GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Net Cash per Share

ContraFect (ContraFect) Net Cash per Share : $-0.88 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ContraFect's Net Cash per Share for the quarter that ended in Sep. 2023 was $-0.88.

The historical rank and industry rank for ContraFect's Net Cash per Share or its related term are showing as below:

During the past 11 years, the highest Price-to-Net-Cash Ratio of ContraFect was 38.93. The lowest was 2.49. And the median was 4.68.

CFRXQ's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.165
* Ranked among companies with meaningful Price-to-Net-Cash only.

ContraFect Net Cash per Share Historical Data

The historical data trend for ContraFect's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Net Cash per Share Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.44 24.63 11.49 75.05 -31.68

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.27 -31.68 -6.26 -0.55 -0.88

Competitive Comparison of ContraFect's Net Cash per Share

For the Biotechnology subindustry, ContraFect's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ContraFect's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ContraFect's Price-to-Net-Cash falls into.



ContraFect Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ContraFect's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(13.682-32.531-0)/0.59498
=-31.68

ContraFect's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

Net Cash per Share (Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(5.413-14.884-0)/10.7048
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ContraFect  (OTCPK:CFRXQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ContraFect Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ContraFect's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421

ContraFect (ContraFect) Headlines

From GuruFocus